GlassScriptPhysician profile
Tarek Kudaimi
NPI 1689638033
$2,541.24
in general payments reported to CMS, 2019-2025
25 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $105 · 2021: $174 · 2022: $146 · 2023: $240 · 2024: $386 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,369.00 | 2019-2025 | |
| Amgen INC. | $488.36 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Janssen Scientific Affairs, LLC | $104.61 | 2019 | |
| Janssen Biotech, INC. | $82.12 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Mallinckrodt Hospital Products INC. | $57.09 | 2020-2025 | Acthar |
| Genzyme Corporation | $40.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.17 | 2025 | Saphnelo |
| Lilly USA, LLC | $32.07 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $30.55 | 2024 | Lupkynis |
| Sobi, INC | $30.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.59 | 2024 | |
| Glaxosmithkline, LLC. | $26.50 | 2019-2025 | Benlysta |
| Pfizer INC. | $25.66 | 2019 | |
| Horizon Therapeutics Plc | $22.36 | 2022 | |
| Organon LLC | $20.77 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.01 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $16.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 2019 | |
| Zyla Life Sciences, INC. | $16.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.62 | 2019 | |
| Hikma Pharmaceuticals USA | $14.44 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.44 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.39 | 2019 | |
| Pacira Therapeutics, INC. | $12.72 | 2020 | |
| Celgene Corporation | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Kudaimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.